Hostname: page-component-7b7567c8c-tnzcf Total loading time: 0 Render date: 2026-11-14T05:58:11.801Z Has data issue: false hasContentIssue false
  • English
  • Français

Clozapine invokes the EGF system to activate ERK: a novel target in treatment resistant schizophrenia?

Published online by Cambridge University Press:  24 June 2014

A Pereira,
G Fink and
S Sundram
A Pereira
Affiliation:
Mental Health Research Institute of Victoria, Melbourne, Australia
G Fink
Affiliation:
Mental Health Research Institute of Victoria, Melbourne, Australia
S Sundram
Affiliation:
Mental Health Research Institute of Victoria, Melbourne, Australia
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Abstracts from ‘Brainwaves’— The Australasian Society for Psychiatric Research Annual Meeting 2006, 6–8 December, Sydney, Australia
Information
Acta Neuropsychiatrica , Volume 18 , Issue 6 , December 2006, pp. 266
Copyright
Copyright © 2006 Blackwell Munksgaard

Background:

The atypical antipsychotic drug clozap-ine is superior to all other drugs in treatment of refractory schizophrenia. This is likely to involve clozapine-inducing long-term neuronal adaptations contingent on drug-receptor activation of intracellular signaling to affect gene transcription. One candidate intracellu-lar signaling pathway is the mitogen-activated protein kinase-extracellular signal-regulated kinase (ERK) cascade. This pathway regulates synaptic proliferation and plasticity, processes impaired in schizophrenia. We have previously reported that although clozapine and haloperidol acutely inhibited ERK activation in cortical neurons, only clozapine stimulated ERK with continued treatment. However, this stimulation was not through the canonical dopamine D2-Gi/o-PKA or the serotonin 5HT2A-Gq-phospholipase C-linked signaling pathways. Thus, we examined alternative signaling pathways that clozapine could mobilize to activate ERK including growth factor receptor systems.

Methods:

Clozapine-induced phosphorylation of ERK1/2 in the absence or presence of growth factor receptor-specific inhibitors was measured in primary murine cortical cultures by Western immunoblotting. Results were normalized against vehicle and total ERK1 and 2 levels.

Results:

The epidermal growth factor (EGF) receptor inhibitor, AG1478, caused significant dose-dependent inhibition of pERK1 (IC50 0.083 μM) and pERK2 (IC50 0.106 mM) in the presence of clozapine, whereas the platelet-derived growth factor receptor inhibitor, tyrphostin, A9 did not.

Conclusions:

This is the first evidence that the effects of clozapine may involve a neuronal signaling system previously not linked to antipsychotic drug action. This presents a novel series of targets for exploration in the development of new therapeutics and insights into the pathology of schizophrenia.